BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize heat therapy to treat cancer, announced today that both the Company's hyperthermia technology and related cancer treatment results were featured prominently at an international scientific conference focused on radiation oncology treatment of cancer. The conference was hosted by the N.N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences (Blokhin Cancer Center), the leading comprehensive cancer center in Russia, and chaired by Professor Mikhail Davydov MD PhD, President of the Russian Academy of Medical Sciences and Director of the Blokhin Cancer Center. The conference, "9th International Scientific Conference – Clinical Oncoradiology," was held on March 12-14, 2014, in Moscow, Russia. The Blokhin Cancer Center comprises four separate institutes, including a 1,600 bed hospital devoted to cancer patients. Blokhin Cancer Center is the largest cancer center in the world and is part of the American-Russian Cancer Alliance, which also includes prominent U.S. cancer treatment centers. The U.S. National Cancer Institute (NCI) provides the infrastructure for the Alliance.

Dr. Gerhard Sennewald, CEO of Medizintechnik GmbH and BSD’s distributor in Russia, co-chaired the scientific session focusing on hyperthermia technology and the clinical benefits of hyperthermia. Dr. Sennewald also delivered an invited presentation titled, "MR Image Guided Hyperthermia: Innovative Interventional Oncology." Dr. Jacoba van der Zee, MD (Erasmus UMS Rotterdam, The Netherlands) presented her seminal work, "Hyperthermia and Radiotherapy in the treatment of Cervical and Breast Cancer." Sultan Rahman, MS (UMS Munich Grosshadern, Germany) gave a presentation titled, "Hyperthermia and Chemotherapy: Soft Tissue Sarcoma and Pancreatic Cancer." Mr. Rahman presented the clinical trial results on hyperthermia and chemotherapy treatment of soft tissue sarcoma and discussed the ongoing, multicenter, randomized, "HEAT" trial using hyperthermia and chemotherapy to treat pancreatic cancer.

“We were excited about the opportunity to showcase BSD's hyperthermia systems at this prestigious international conference hosted by the preeminent Blokhin Cancer Center," stated Dr. Gerhard Sennewald. "Russia and the GIS countries have a long history in the use of hyperthermia in clinical oncology, and it is always rewarding to share in their in-depth knowledge of hyperthermia."

Russia has a population of 149 million and is a potentially lucrative market for medical device companies. The Russian market for medical equipment and supplies is estimated at $6 billion, which puts the Russian market among the top 20 in the world. Approximately 73% of the medical equipment market in Russia is supplied by non-Russian manufacturers, with the United States, Germany, Japan, and China the leading suppliers.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.

.

BSD Medical CorporationWilliam Barth, 801-972-5555investor@bsdmc.comfax: 801-972-5930